NCT06978777 Effect of Caffeine on Cold-stimulated Brown Adipose Tissue Activity
| NCT ID | NCT06978777 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Basel, Switzerland |
| Condition | Brown Adipose Tissue (BAT) Physiology |
| Study Type | INTERVENTIONAL |
| Enrollment | 12 participants |
| Start Date | 2026-01-21 |
| Primary Completion | 2026-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 12 participants in total. It began in 2026-01-21 with a primary completion date of 2026-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the study is to asses brown adipose tissue activity after a cold mild stimulus, preceded by 200mg caffeine or placebo administration.
Eligibility Criteria
Inclusion Criteria: * BMI 18.5 to 25 kg/m2 * Able to give informed consent as documented by signature * Moderate caffeine consumption (1 to 3 cups of coffee per day) * Increase of EE in response to mild cold of ≥ 5% of REE Exclusion Criteria: * Known hypersensitivity or allergy to caffeine * Concomitant medication other than prescription free analgesics (paracetamol and NSAID) and oral contraceptives * Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, cardiac arrhythmia, hypertension, diabetes mellitus, hyper- or hypothyroidism) * History of depressive disorder or anxiety disorder * Smoker / habitual tobacco use * Habitual excessive alcohol use * Regular consumption of caffeine containing energy drinks * Weight change of \>5% within 3 months prior to inclusion * Systolic blood pressure \>140 mmHg and/or diastolic blood pressure \> 95 mmHg. * Resting heart rate \>90 bpm * Hypersensitivity to cold (e.g. Raynaud syndrome) * Known or suspected non-compliance, drug or alcohol abuse * Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant. * Enrolment of the investigator, his/her family members, employees, and other dependent persons * Enrolment into another study using ionizing radiation within the previous 12 months. * Pregnancy or lactation
Contact & Investigator
Matthias Betz, Prof.
PRINCIPAL INVESTIGATOR
University Hospital, Basel, Switzerland
Frequently Asked Questions
Who can join the NCT06978777 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 40 Years, studying Brown Adipose Tissue (BAT) Physiology. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06978777 currently recruiting?
Yes, NCT06978777 is actively recruiting participants. Contact the research team at Matthias.Betz@usb.ch for enrollment information.
Where is the NCT06978777 trial being conducted?
This trial is being conducted at Basel, Switzerland.
Who is sponsoring the NCT06978777 clinical trial?
NCT06978777 is sponsored by University Hospital, Basel, Switzerland. The principal investigator is Matthias Betz, Prof. at University Hospital, Basel, Switzerland. The trial plans to enroll 12 participants.